AstraZeneca's Tagrisso combined with chemotherapy showed a statistically significant and clinically meaningful overall survival benefit over Tagrisso monotherapy in first-line advanced EGFR-mutated non-small cell lung cancer (NSCLC), according to the final analysis of the phase 3 Flaura2 trial23.
At 57% data maturity, the Tagrisso/chemo combo achieved a median overall survival of 47.5 months compared to 37.6 months for Tagrisso alone, with three-year survival rates of 63% vs 51%3.
Johnson & Johnson's Rybrevant plus Lazcluze regimen, tested in the MARIPOSA study, achieved a highly statistically significant 25% lower risk of death compared to Tagrisso monotherapy, positioning it as a potent competitor to AstraZeneca's regimen in first-line EGFR-mutated NSCLC4.
Both AstraZeneca's Tagrisso/chemo combo and J&J's Rybrevant/Lazcluze doublet are approved for this indication, but currently only J&J’s regimen has overall survival (OS) data listed on its US label34.
Recent clinical presentations have intensified competition in the EGFR-mutated lung cancer treatment market, with Tagrisso remaining a backbone therapy and rivalry focused on survival and tolerability outcomes234.
Sources:
2. https://www.fiercepharma.com/pharma/astrazeneca-facing-lung-cancer-challenge-jj-touts-life-extension-benefit-tagrisso-combo
3. https://www.oncologypipeline.com/apexonco/world-lung-2025-crossing-curves-lung-cancer
4. https://www.biospace.com/drug-development/j-js-lung-cancer-combo-bests-astrazenecas-tagrisso-reducing-risk-of-death-25